Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

David J. Curtis(Pomona College), Geoffrey R. Hill(University of Washington Medical Center), David T Yeung(Royal Adelaide Hospital), David Gottlieb(The University of Sydney), Siok‐Keen Tey(The University of Queensland), Clinton Lewis(Auckland City Hospital), Rachel Koldej(The Royal Melbourne Hospital), John Reynolds(The Alfred Hospital), Duncan Purtill(Fiona Stanley Hospital), Richard De Abreu Lourenço(University of Technology Sydney), Catherine Morrissey(Alfred Health), Eric Wong(Austin Health), Travis Perera(Wellington Hospital), Sushrut Patil(Alfred Health), Andrea Arenas(Australasian Leukaemia and Lymphoma Group), John Stubbs(Australasian Leukaemia and Lymphoma Group), Nadia Munsef(Australasian Leukaemia and Lymphoma Group), John J. Moore(Health Net)
New England Journal of Medicine
June 13, 2025
10.1056/nejmoa2503189
Cited by 52

Related Papers

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation
|Blood|2010|517
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study
|Nature Medicine|2020|289
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
|Blood|2018|208